Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2025-12-25 @ 9:10 PM
Study NCT ID:
NCT06088056
Status:
NOT_YET_RECRUITING
Last Update Posted:
2023-10-18
First Post:
2023-07-30
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001943', 'term': 'Breast Neoplasms'}, {'id': 'D001932', 'term': 'Brain Neoplasms'}], 'ancestors': [{'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D001941', 'term': 'Breast Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D016543', 'term': 'Central Nervous System Neoplasms'}, {'id': 'D009423', 'term': 'Nervous System Neoplasms'}, {'id': 'D001927', 'term': 'Brain Diseases'}, {'id': 'D002493', 'term': 'Central Nervous System Diseases'}, {'id': 'D009422', 'term': 'Nervous System Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 17}}, 'statusModule': {'overallStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2023-11', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-10', 'completionDateStruct': {'date': '2026-07', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2023-10-14', 'studyFirstSubmitDate': '2023-07-30', 'studyFirstSubmitQcDate': '2023-10-14', 'lastUpdatePostDateStruct': {'date': '2023-10-18', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2023-10-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2024-06', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Intracranial objective response rate(IC-ORR)', 'timeFrame': '2 years', 'description': 'Proportion of participants with a complete response (CR) or partial response (PR) for intracranial tumors as defined by response assessment in neuro-oncology brain metastases (RANO-BM) criteria.'}], 'secondaryOutcomes': [{'measure': 'Intracranial CNS Progression Free Survival(IC-PFS)', 'timeFrame': '2 years', 'description': 'Time from treatment until the first date of intracranial disease progression or death due any cause. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.'}, {'measure': 'Progression Free Survival(PFS)', 'timeFrame': '2 years', 'description': 'Time from treatment until the first date of intracranial or extracranial disease progression or death due any cause. For participants whose disease has not progressed at the time of the analysis, censoring will be performed using the date of the last valid disease assessment.'}, {'measure': 'Overall survival(OS)', 'timeFrame': '3 years', 'description': 'Time from the treatment until to the date of death, regardless of the cause of death'}, {'measure': 'Percentage of Participants With Adverse Events Percentage of Participants With Adverse Events', 'timeFrame': '2 years', 'description': 'Treatment-related adverse events were assessed and graded according to CTCAE v. 5.0'}, {'measure': 'Health-related quality of life per FACT-BR', 'timeFrame': '2 years', 'description': 'Health-related quality of life was evaluated using the QLQ-C30 questionnaires to assess Health-related quality of life was evaluated using the FACT-BR questionnaires to assess the quality of life'}, {'measure': 'Local control rate', 'timeFrame': '2 years', 'description': 'The percentage of participants who have achieved complete response, partial response and stable disease according to RANO-BM criteria after treatment'}, {'measure': 'Neurocognitive function per HVLT-R', 'timeFrame': '2 years', 'description': 'Neurocognitive function was evaluated using HVLT-R test'}]}, 'oversightModule': {'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Breast Cancer', 'Brain Metastases', 'Radiotherapy']}, 'descriptionModule': {'briefSummary': 'This research study will evaluate the efficacy and safety of stereotactic radiotherapy (SRT) combined with Trastuzumab-Deruxtecan (T-DXd; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases.'}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Pathologically confirmed HER2 positive advanced breast cancer\n* Age\\>18 years.\n* Brain metastases confirmed by enhanced brain MRI. Metastases number less than 15.\n* KPS≥70 or KPS ≥60 with neurologic symptoms caused by BM\n* Life expectancy of more than 6 months\n* Prior therapy of oral dexamethasone not exceeding 16mg/d\n* Time interval from prior therapy was more than 2 weeks, and evaluation of adverse events is no more than grade 1.\n* Screening laboratory values must meet the following criteria( and should be obtained within 28 days prior to registration):\n\n 1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L, Platelets≥ 90 x 109/L, Hemoglobin ≥ 90 g/L\n 2. Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ≤2.5 x ULN without liver metastasis,≤ 5 x ULN with liver metastases\n 3. Serum BUN and creatinine ≤ 1.5 x Upper Limit of Normal (ULN)\n 4. LVEF ≥ 50%\n 5. QTcF \\< 480 ms\n 6. INR≤1.5×ULN，APTT≤1.5×ULN\n* Signed the informed consent form prior to patient entry\n\nExclusion Criteria:\n\n* Leptomeningeal or hemorrhagic metastases\n* Uncontrolled epilepsy\n* Severe or uncontrolled disease: severe cardiovascular disease, end-stage renal disease, severe hepatic disease, history of immunodeficiency, including HIV positive, active HBV/HCV or other acquired congenital immunodeficiency disease, or organ transplantation history, active infection, etc.\n* History of allergy to treatment regimens\n* Pregnancy or lactation period， women of child-bearing age who are unwilling to accept contraceptive measures.\n* Inability to complete enhanced MRI\n* Not suitable for inclusion for specific reasons judged by sponsor'}, 'identificationModule': {'nctId': 'NCT06088056', 'briefTitle': 'A Phase II Study of T-DXd Plus SRT in HER2-positive Breast Cancer Brain Metastases', 'organization': {'class': 'OTHER', 'fullName': 'Fudan University'}, 'officialTitle': 'A Phase II Study of T-DXd Plus Stereotactic Radiotherapy(SRT) in HER2-positive Breast Cancer Brain Metastases', 'orgStudyIdInfo': {'id': 'FDRT-BC021'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Combination use of SRT with T-DXd', 'description': "Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.\n\nDose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg", 'interventionNames': ['Drug: Combination use of SRT with T-DXd']}], 'interventions': [{'name': 'Combination use of SRT with T-DXd', 'type': 'DRUG', 'description': "Radiation therapy SRT will be implemented according to investigator's clinical practice(based on brain metastases number and tumor volume). T-DXd(5.4mg/kg, once per 21 days, initiated within 2 weeks after SRT) will be provided to patients with confirmed HER2 positive breast cancer and brain metastasis until tumor progression, a severe adverse event deemed related to the study drug, or death. All dose adjustments should be based on the most severe toxicity level (CTCAE version 5.0) that occurred. Two doses are allowed to be reduced.\n\nDose Level 0: 5.4mg/kg Dose Level 1 :4.4mg/kg Dose Level 2: 3.2mg/kg", 'armGroupLabels': ['Combination use of SRT with T-DXd']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Shanghai', 'country': 'China', 'contacts': [{'name': 'Zhaozhi yang, PhD', 'role': 'CONTACT', 'email': 'yzzhi2014@163.com', 'phone': '+8618017317126'}, {'name': 'Jin Meng, PhD', 'role': 'CONTACT', 'email': 'jinmeng@fudan.edu.cn', 'phone': '+8618121299532'}, {'name': 'Zhaozhi Yang, PhD', 'role': 'PRINCIPAL_INVESTIGATOR'}], 'facility': 'Fudan University Shanghai Cancer Center', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}], 'centralContacts': [{'name': 'Zhaozhi Yang', 'role': 'CONTACT', 'email': 'yzzhi2014@163.com', 'phone': '+8618017317126'}], 'overallOfficials': [{'name': 'Zhaozhi Yang', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Fudan University'}, {'name': 'Jiayi Chen', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Ruijin Hospital affiliated to Shanghai Jiaotong University'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Fudan University', 'class': 'OTHER'}, 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Clinical Professor', 'investigatorFullName': 'Xiaoli Yu', 'investigatorAffiliation': 'Fudan University'}}}}